Compounds > 3-methoxy-o-demethylencainide
Page last updated: 2024-12-06

3-methoxy-o-demethylencainide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-methoxy-O-demethylencainide: encainide metabolite with longer half-life; identified in plasma of patient receiving encainide orally; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54737
CHEMBL ID2106770
SCHEMBL ID120888
MeSH IDM0104275

Synonyms (39)

Synonym
modecainidum [inn-latin]
mj 14030
(+-)-4-hydroxy-3-methoxy-n-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide
modecainide
(+-)-2'-(2-(1-methyl-2-piperidyl)ethyl)vanillanilide
bmy 40327
modecainide [usan:inn]
benzamide, 4-hydroxy-3-methoxy-n-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)-, (+-)-
3-methoxy-o-demethylencainide
modecainida [inn-spanish]
D05065
modecainide (usan/inn)
81329-71-7
4-hydroxy-3-methoxy-n-[2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl]benzamide
mj-14030
benzamide, 4-hydroxy-3-methoxy-n-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)-
3-methoxy-o-desmethylencainide
82522-70-1
bmy-40327
modecainidum
modecainida
unii-ju27887fwk
ju27887fwk ,
CHEMBL2106770
SCHEMBL120888
benzamide, 4-hydroxy-3-methoxy-n-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)-, (+/-)-
modecainide [usan]
modecainide [inn]
(+/-)-2'-(2-(1-methyl-2-piperidyl)ethyl)vanillanilide
HY-101723
CS-6629
AKOS030549012
bmy 40327;mj 14030
2'-(2-(1-methyl-2-piperidyl)ethyl)vanillanilide
Q27281703
4-hydroxy-3-methoxy-n-(2-(2-(1-methylpiperidin-2-yl)ethyl)phenyl)benzamide
MS-25916
DTXSID20868609
4-hydroxy-3-methoxy-n-{2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl}benzamide

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacodynamic characteristics of 3-methoxy-O-demethyl encainide (MODE) were studied in instrumented, chloralose-anesthetized dogs."( Pharmacodynamic modeling of antiarrhythmic drug effects--application to 3-methoxy-O-demethyl encainide.
Davy, JM; Dorian, P; Kates, RE, )		0.13
" Data from in vitro and animal studies have indicated that MODE has electrophysiologic and pharmacokinetic features that make its further evaluation desirable; in earlier studies, we found that MODE suppressed chronic high-frequency nonsustained ventricular arrhythmias at plasma concentrations of 50-160 ng/ml."( Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
Echt, DS; Lee, JT; Roden, DM; Woosley, RL, 1989)		0.28

Bioavailability

ExcerptReferenceRelevance
"The bioavailability of drugs that undergo extensive presystemic hepatic metabolism may be increased by concomitant ingestion with food."( Impact of food on the bioavailability of encainide.
Destache, CJ; Hilleman, DE; Malesker, MA; Mohiuddin, SM; Nipper, HC; Stoysich, AM, 1992)		0.28

Dosage Studied

ExcerptRelevanceReference
" Twenty-four-hour ambulatory ECGs were obtained at baseline for each daily dosage of 75 mg, 150 mg, and 225 mg of encainide during the in-hospital titration period and at the end of the first and sixth months during the follow-up period."( Long-term efficacy and safety of oral encainide in the treatment of chronic ventricular ectopic activity: relationship to plasma concentrations--a French multicenter trial.
Barnay, C; Cheymol, G; Coumel, P; Dumoulin, P; Flammang, D; Jaillon, P; Kher, A; Medvedowsky, JL; Poirier, JM; Valty, J, 1985)		0.27
" Three-times-a-day dosing was as effective as 4-times-a-day dosing."( Dosing recommendations for encainide.
Antonaccio, MJ; Verjee, S, 1986)		0.27
" Encainide biotransformation is impaired in hepatic disease, but no major dosage changes are required."( Clinical pharmacokinetics of encainide.
Roden, DM; Woosley, RL, 1988)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (80.00)18.7374
1990's4 (20.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.94 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (21.74%)5.53%
Reviews3 (13.04%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (65.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
flecainide
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.. flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).		1.9710aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines		anti-arrhythmia drug
adenosine diphosphate
Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.		1.9710adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
encainide
Encainide: One of the ANTI-ARRHYTHMIA AGENTS, it blocks VOLTAGE-GATED SODIUM CHANNELS and slows conduction within the His-Purkinje system and MYOCARDIUM.. encainide : 4-Methoxy-N-phenylbenzamide in which the hydrogen at the 2 position of the phenyl group is substituted by a 2-(1-methylpiperidin-2-yl)ethyl group. A class Ic antiarrhythmic, the hydrochloride was used for the treatment of severe or life-threatening ventricular arrhythmias, but it was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack and was withdrawn from the market.		9.04205benzamides;
piperidines		anti-arrhythmia drug;
sodium channel blocker
o-demethylencainide
O-demethylencainide: encainide metabolite with longer half-life; identified in plasma of patient receiving encainide orally; RN given refers to cpd without isomeric designation		8.28164
ConditionIndicatedRelationship StrengthStudiesTrials
Arrhythmia
[description not available]		05.9352
Arrhythmias, Cardiac
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.		05.9352
Tachycardia, Supraventricular
A generic expression for any tachycardia that originates above the BUNDLE OF HIS.		03.3611
Coronary Thrombosis
Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION.		01.9710
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		01.9710
Chronic Illness
[description not available]		03.3511
Cardiac Complex, Premature
[description not available]		03.3511
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		03.3511
Cardiovascular Stroke
[description not available]		01.9710
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		01.9710
Tachyarrhythmia
[description not available]		02.3720
Tachycardia
Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.		02.3720
Ventricular Fibrillation
A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.		01.9710
Cirrhosis, Liver
[description not available]		02.8810
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		03.7620
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.		02.8810
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.8810
Liver Dysfunction
[description not available]		02.8810
Liver Diseases
Pathological processes of the LIVER.		02.8810